SmallCaps
ASX:MEMPharmaceuticals, Biotechnology & Life SciencesLife Sciences Tools & Services

Memphasys Ltd

$0.006
Day Range
$0.006 – $0.006
52 Week Range
$0.003 – $0.009
Volume
314.01K
Avg Volume (10D)
1.01M
Market Cap
$18.52M

Price Chart

OHLC · volume · moving averages

$0.006+$0.000 (+0.00%)over 6M
Hi$0.009Lo$0.004
Price-sensitive newsVolumePrev close · 52W range

Market Statistics

Today's trading range

Open
$0.006
Previous Close
$0.006
Day High
$0.006
Day Low
$0.006
52 Week High
$0.009
52 Week Low
$0.003

Valuation

Fundamental multiples

Market Cap
18.52M
Shares Outstanding
3.09B
Price to Book
4.01

Trading Activity

Volume & order book

Volume
314.01K
Value Traded
1.88K
Bid
$0.006 × 8,313,884
Ask
$0.007 × 7,186,185

Performance

Returns across timeframes

1 Day
0.00%
5 Day
0.00%
13 Week
50.00%
52 Week
57.50%
YTD
-14.29%

Technical Indicators

Momentum & moving averages

RSI (14)
42.66
50-Day SMA
$0.007
200-Day SMA
$0.006

— From the desk

Latest News

Memphasys Signs Agreement to Distribute Felix Fertility Device Across Middle East and North Africa
Biotechnology

Memphasys Signs Agreement to Distribute Felix Fertility Device Across Middle East and North Africa

Memphasys (ASX: MEM) has granted Qatar-based company International Technical Legacy (ITL) exclusive commercial and distribution rights to its innovative Felix male fertility sperm preparation system. The five-year deal applies to approximately 353 clinics across 15 countries across the Middle East and North Africa, which perform a cumulative 140,000 in vitro fertilisation (IVF) cycles per year. […]

Memphasys pilot study confirms RoXsta’s potential as high-throughput antioxidant diagnostic tool
Biotechnology

Memphasys pilot study confirms RoXsta’s potential as high-throughput antioxidant diagnostic tool

A pilot study has shown that Memphasys’ (ASX: MEM) RoXsta Mega Cell high-throughput assay device can conduct large-scale, simultaneous antioxidant assays within a lab setting. The study demonstrated that the next-generation analytical platform was able to process 96 samples in less than one hour, returning highly accurate antioxidant readings for individuals requiring antioxidant therapy. The […]

Memphasys achieves key milestone with clinical validation of Felix fertility device
Biotechnology

Memphasys achieves key milestone with clinical validation of Felix fertility device

Memphasys (ASX: MEM) has published positive data from a pivotal clinical trial of its Felix electrophoresis-based sperm separation device for use in assisted reproduction. The trial validated the ability of the Felix device to meet and exceed industry benchmarks and found it to be non-inferior to the “swim-up” technique but statistically superior to DGC (density-gradient […]

Peer review confirms Memphasys’ Felix system superior to conventional sperm preparation for human IVF
Biotechnology

Peer review confirms Memphasys’ Felix system superior to conventional sperm preparation for human IVF

In vitro results from study findings on the Felix system developed by reproductive biotechnology company Memphasys (ASX: MEM) have demonstrated it can outperform conventional sperm preparation methods for human IVF (in vitro fertilisation) procedures. Two articles by key opinion leaders (KOL) evaluating the Felix system device have found the system is superior to the density […]